Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

被引：0

作者：

Harada, Takeshi ^{[1
]}

Oda, Asuka ^{[1
]}

Ohguchi, Hiroto ^{[2
]}

Grondin, Yohann ^{[3
]}

Tenshin, Hirofumi ^{[4
]}

Hiasa, Masahiro ^{[4
]}

Teramachi, Jumpei ^{[5
]}

Oura, Masahiro ^{[1
]}

Sogabe, Kimiko ^{[1
]}

Fujii, Shiro ^{[1
]}

Nakamura, Shingen ^{[1
]}

Miki, Hirokazu ^{[6
]}

Kagawa, Kumiko ^{[1
]}

Ozaki, Shuji ^{[7
]}

Hideshima, Teru ^{[8
]}

Anderson, Kenneth C. ^{[8
]}

Abe, Masahiro ^{[1
]}

机构：

[1] Tokushima Univ, Inst Biomed Sci, Dept Hematol Endocrinol & Metab, Grad Sch, Tokushima, Japan

[2] Kumamoto Univ, Div Dis Epigenet, IRDA, Kumamoto, Japan

[3] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA USA

[4] Tokushima Univ, Inst Biomed Sci, Dept Orthodont & Dentofacial Orthoped, Grad Sch, Tokushima, Japan

[5] Tokushima Univ, Inst Biomed Sci, Dept Tissue Regenerat, Grad Sch, Tokushima, Japan

[6] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Japan

[7] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Japan

[8] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-127679

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3111

引用

页数：3

共 50 条

[21] Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target for Patients with Rheumatoid Arthritis
Goschl, Lisa
Bonelli, Michael
Saferding, Victoria
Peglej, Teresa
Knapp, Sylvia
Backlund, Johan
Bock, Christoph
Matthias, Patrick
Hirahara, Kiyoshi
Scheinecker, Clemens
Steiner, Guenter
Smolen, Josef S.
Ellmeier, Wilfried
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[22] Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis
Goschl, Lisa
Saferding, Victoria
Backlund, Johan
Scheinecker, Clemens
Smolen, Josef S.
Steiner, Guenter
Ellmeier, Wilfried
Bonelli, Michael
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[23] Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
Thomas, Elizabeth A.
PHARMACEUTICALS, 2014, 7 (06): : 634 - 661
[24] PIM2 kinase regulates TIGIT expression and energy metabolism in NK cells from multiple myeloma patients
Wang, Hao
Liu, Zhaoyun
Fu, Rong
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S157 - S157
[25] Targeting Ubiquitin Pathway: Novel Therapeutic Approaches for Multiple Myeloma
Ghannam-Shahbari, Dima
Brik, Ashraf
Saadi, Sahar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S190 - S191
[26] Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy
Harada, Takeshi
Oda, Asuka
Tenshin, Hirofumi
Teramachi, Jumpei
Oura, Masahiro
Sogabe, Kimiko
Fujii, Shiro
Nakamura, Shingen
Miki, Hirokazu
Kagawa, Kumiko
Ozaki, Shuji
Hideshima, Teru
Anderson, Kenneth C.
Abe, Masahiro
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10):
[27] HDAC1, a novel marker for benign teratomas
Simboeck, Elisabeth
Di Croce, Luciano
EMBO JOURNAL, 2010, 29 (23): : 3893 - 3895
[28] EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
Adamik, Juraj
Jin, Shunqian
Sun, Quanhong
Zhang, Peng
Weiss, Kurt R.
Anderson, Judith L.
Silbermann, Rebecca
Roodman, G. David
Galson, Deborah L.
MOLECULAR CANCER RESEARCH, 2017, 15 (04) : 405 - 417
[29] Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Stubbs, Matthew C.
Kim, Wonil
Bariteau, Megan
Davis, Tina
Vempati, Sridhar
Minehart, Janna
Witkin, Matthew
Qi, Jun
Krivtsov, Andrei V.
Bradner, James E.
Kung, Andrew L.
Armstrong, Scott A.
CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2348 - 2358
[30] HDAC inhibition in combination with MEK or BCL-2 inhibition as novel therapeutic strategies in multiple myeloma
Miller, Kevin C.
Haug, Jessica
Kimlinger, Teresa
Kumar, Sanjay
Gonsalves, Wilson
Rajkumar, S. Vincent
Kumar, Shaji K.
Ramakrishnan, Vijay
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →